Skip to content
Screener

Common Stock at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
500M0.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0-100%
RFL
Rafael Holdings, Inc.RFL
$9.4M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$18K0.0%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$1K0.0%
XER
Xeris Biopharma Holdings, Inc.XERS
$18K+12.5%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$681.73M+6.6%
Enterprise value$537.9M-17.8%
P/E11.7×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValueOutstanding.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemJune 30,2026December 31,2025
Stockholders’ equity:
Preferred stock:
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2026, or December 31, 2025
Common stock, $0.0001 par value, 250,000,000 shares authorized; 60,917,598 shares issued and 59,341,906 shares outstanding as of June 30, 2026; 58,338,319 shares issued and 56,854,781 shares outstanding as of December 31, 202566
Additional paid-in capital606,264588,458
Treasury stock, at cost(10,983)(10,983)
Accumulated deficit(375,418)(422,060)
Accumulated other comprehensive loss(2,217)(764)

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s common stock?
Zevra Therapeutics, Inc. (ZVRA) reported common stock of $6K in Q2 2026.
How has Zevra Therapeutics, Inc.'s common stock changed year-over-year?
Zevra Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from $6K to $6K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Zevra Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude